Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire December 18, 2025 SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on […]

Mission Produce(R) Announces Leadership Succession and Provides Update on Board Refreshment Initiative

Mission Produce(R) Announces Leadership Succession and Provides Update on Board Refreshment Initiative GlobeNewswire December 18, 2025 Founder & CEO Steve Barnard to Transition to Executive Chairman of the Board; President and COO John Pawlowski to Become CEO at the close of the Annual Meeting of Shareholders in April 2026 Board Refreshment Initiative Underway -Three New

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire December 18, 2025 CONSHOHOCKEN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on December 15, 2025 to 4 new

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease Event to be held January 6th, 2026, at 10 a.m. EST GlobeNewswire December 18, 2025 BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire December 18, 2025 SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan Healthcare Conference being held

Parsons Names John Martinez as the Company’s Next Chief Legal Officer

Parsons Names John Martinez as the Company's Next Chief Legal Officer GlobeNewswire December 18, 2025 CHANTILLY, Va., Dec. 18, 2025 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE:PSN) has named proven executive and legal expert John Martinez as the company's next chief legal officer (CLO), effective February 16, 2026. The announcement follows the notification by current CLO

vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D GlobeNewswire December 18, 2025 HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) — vTv

Abivax to be Added to Nasdaq Biotechnology Index

Abivax to be Added to Nasdaq Biotechnology Index GlobeNewswire December 18, 2025 Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness

NANO Nuclear Reports Fiscal Year 2025 Financial Results and Provides Business Update

NANO Nuclear Reports Fiscal Year 2025 Financial Results and Provides Business Update GlobeNewswire December 18, 2025 Management to hold webcast today at 5:00 pm Eastern New York, N.Y., Dec. 18, 2025 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor and technology company

Safe Harbor Financial Statement on Federal Cannabis Rescheduling and the Resulting Growth Opportunity for Its Banking Platform

Safe Harbor Financial Statement on Federal Cannabis Rescheduling and the Resulting Growth Opportunity for Its Banking Platform Improved operator economics and expanding institutional interest position Safe Harbor for scalable, compliant growth GlobeNewswire December 18, 2025 DENVER, Dec. 18, 2025 (GLOBE NEWSWIRE) — SHF Holdings, Inc., d/b/a Safe Harbor Financial (NASDAQ: SHFS) (“Safe Harbor” or the

Scroll to Top